0
2019
Acute Lymphocytic-lymphoblastic Leukemia (all) Therapeutics Market

Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market

by Drug (Hyper-CVAD Regimen, Linker Regimen, Nucleoside Metabolic Inhibitors, Targeted Drugs & Immunotherapy, CALGB 8811 Regimen, and Oncaspar), and Type (Pediatric and Adult): Global Opportunity Analysis and Industry Forecast, 2019-2026

Report Code: A00460
Pages: 113
Tables: 50
Charts: 30
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

Acute Lymphocytic/lymphoblastic Leukemia Therapeutics Market Outlook - 2026

The global acute lymphocytic/lymphoblastic leukemia therapeutics market accounted for $2,334.5 million in 2018, and is expected to reach $3,528.8 million by 2026, registering a CAGR of 5.3% from 2019 to 2026.

Acute lymphocytic/lymphoblastic leukemia (ALL) is a type of cancer that develops from immature lymphocytes. “Acute” here indicates leukemia that quickly progresses and spreads across the body. ALL develops in bone marrow and quickly invades other parts of the body including the liver, spleen, lymph nodes, liver, central nervous system, spleen, central nervous system, and the blood. Symptoms can be non-specific and may include feeling weak and tired, paler skin, bruises, frequent and severe bleeding gums, nose bleeds; weight loss, shortness of breath, and loss of appetite. Various types of therapeutics are used for ALL treatment. Chemotherapy is one of the major therapeutics used for ALL treatment.

The market is experiencing growth owing to rise in incidences of acute lymphoblastic leukemia and the number of bone marrow biopsies across the world. In addition, the increase in investment in the R&D of different leukemia and rise in awareness of targeted therapies amongst the population further drive the growth of the ALL therapeutics market. Despite these, the stringent regulatory approvals for the therapeutics and the adverse side effects of the drugs used in the therapy impede the growth of the market worldwide. Also, patent expiry of the blockbuster drugs used in the treatment and the higher costs involved in the therapies limit the growth of the global ALL therapeutics market. Nonetheless, the rise in number of clinical trials and new product approvals are anticipated to create newer opportunities in the emerging as well as the developed markets.

Acute Lymphocytic/lymphoblastic Leukemia Therapeutics Market Segmentation

The acute lymphocytic/lymphoblastic leukemia therapeutics market is segmented based on drug, type, and region to provide a detailed assessment of the market. Based on drug, the market is divided into Hyper-CVAD Regimen, Linker Regimen, Nucleoside Metabolic Inhibitors (Clolar and Nelarabine), Targeted Drugs & Immunotherapy, CALGB 8811 Regimen, and Oncaspar. Based on type, it is classified into pediatrics and adults. Based on region, the acute lymphocytic/lymphoblastic leukemia therapeutics market size is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market

Segment review

Based on drug, the market is divided into Hyper-CVAD Regimen, Linker Regimen, Nucleoside Metabolic Inhibitors (Clolar and Nelarabine), Targeted Drugs & Immunotherapy, CALGB 8811 Regimen, and Oncaspar. The Hyper-CVAD Regimen acquired the largest acute lymphocytic/lymphoblastic leukemia therapeutics market share in 2018 owing to wide usage in the ALL treatment. Hyper-CVAD Regimen is considered as one of the most commonly used therapy options for acute lymphocytic/lymphoblastic leukemia.

Furthermore, targeted drugs & immunotherapy are projected to grow at the fastest rate during the forecast period as these drugs have shown potential in the treatment of relapsed acute lymphocytic leukemia and is widely used in patients who do not respond to chemotherapy. Therefore, these factors contribute toward the growth of the ALL therapeutics market.

Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market by Drugs

According to type, the pediatrics segment generated the highest revenue in 2018 and is expected to maintain its dominance throughout the forecast period. This is attributed to the high incidences of acute lymphocytic/lymphoblastic leukemia among pediatric population. Acute lymphocytic/lymphoblastic leukemia is considered as one of the most common cancer types in pediatric population. Moreover, pediatric population have higher success rate for acute lymphocytic/lymphoblastic leukemia treatments.

Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market by Type

North America occupied the largest share of the market in 2018 and is expected to maintain its dominance during the forecast period owing to easy availability of treatments, high cost of treatments, and presence of majority of key players. However, Asia-Pacific is expected to witness the highest growth rate throughout the forecast period, due to its high population base and rise in patient awareness toward cancer care.

Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market by Region

The major companies profiled in this report include Amgen, Inc., Bristol-Myers Squibb Company, Erytech Pharma, Leadiant Biosciences, Inc. (Sigma-Tau Pharmaceuticals Inc.), Novartis AG, Pfizer, Inc., Rare Disease Therapeutics, Inc., Sanofi, Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.

Key Market Benefits for Acute Lymphocytic/lymphoblastic Leukemia Therapeutics Market:

  • This report entails a detailed quantitative analysis along with the current acute lymphocytic/lymphoblastic leukemia therapeutics market trends from 2018 to 2026 to identify the prevailing opportunities along with the strategic assessment of the global acute lymphocytic/lymphoblastic leukemia therapeutics market growth.
  • The market forecast is studied from 2019 to 2026.
  • The market size and estimations are based on a comprehensive analysis of key developments in the acute lymphocytic/lymphoblastic leukemia therapeutics industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Report Highlights

Aspects Details
By Type
  • Pediatrics
  • Adults
By Drug
  • Hyper-CVAD Regimen
  • Linker Regimen
  • Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
  • Targeted Drugs & Immunotherapy
  • CALGB 8811 Regimen
  • Oncaspar
By Region
  • North America 
  • Europe 
  • Asia-Pacific 
  • LAMEA 
Key Market Players PFIZER, INC, AMGEN, INC, BRISTOL-MYERS SQUIBB COMPANY, SANOFI, ERYTECH PHARMA, RARE DISEASE THERAPEUTICS, INC., SPECTRUM PHARMACEUTICALS, INC, TAKEDA PHARMACEUTICAL COMPANY LIMITED, NOVARTIS AG, LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.)
 

Loading Table Of Content...


 
 

Acute lymphocytic/lymphoblastic leukemia therapeutics (ALL) is one of the most common acute leukemia in children and adults. Newer lab techniques and targeted therapy drugs against ALL are now being developed. The targeted therapy drugs are now becoming an important part in the ALL therapeutics market as they work differently from standard chemotherapy drugs by targeting specific gene inside normal bone marrow cells. Asia-Pacific is projected to register highest growth rate in the global acute lymphocytic/lymphoblastic leukemia therapeutics market due to massive increase in population, high prevalence of lymphoblastic leukemia, and rise in the healthcare market.

Rise in incidence rates and increase in prevalence rates of lymphoblastic leukemia, implementation of national screening programs, and support in reimbursement for ALL therapeutics are the major factors that drive the growth of the market. However, high costs associated with the treatment for cancer refrain patients from diagnosis and treatment. Moreover, side effects of the drugs used in the therapies significantly limits the diagnosis of lymphoblastic leukemia. Such factors are expected to restrain the market growth.

Purchase Options

Call or Email Us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
Related Tags

Purchase Full Report of
Acute Lymphocytic-lymphoblastic Leukemia (all) Therapeutics Market

Start reading instantly.
This Report and over 71,321+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Jun 2020 - Jun 2021)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jun 2020 - Jun 2021)
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jun 2020 - Jun 2021)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jun 2020 - Jun 2021)
  • Enterprise
    License/PDF

  • $10,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jun 2020 - Jun 2021)
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

Related Reports
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of the scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time for readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of the scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save the time of readers